Lonza Group AG (LONN.SW) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. LONN.SW files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.09% | 30.00% | Pass |
| Interest-bearing investments | 1.78% | 30.00% | Pass |
| Non-permissible income | 0.66% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 27.34% | 33.00% | Pass |
| Interest-bearing investments | 4.02% | 33.00% | Pass |
| Non-liquid assets | 90.05% | at least 20.00% | Pass |
| Non-permissible income | 0.66% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 27.34% | 33.33% | Pass |
| Cash + interest-bearing securities | 4.02% | 33.33% | Pass |
| Accounts receivable | 9.95% | 33.33% | Pass |
| Non-permissible income | 0.66% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 27.34% | 33.33% | Pass |
| Cash + interest-bearing securities | 4.02% | 33.33% | Pass |
| Accounts receivable | 9.95% | 50.00% | Pass |
| Non-permissible income | 0.66% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.79% | 33.00% | Pass |
| Cash + interest-bearing securities | 1.73% | 33.00% | Pass |
| Accounts receivable | 2.56% | 33.00% | Pass |
| Non-permissible income | 0.66% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.40% | 33.00% | Pass |
| Cash + interest-bearing securities | 1.82% | 49.00% | Pass |
| Accounts receivable | 2.69% | 49.00% | Pass |
| Non-permissible income | 0.66% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.40% | 33.33% | Pass |
| Cash + interest-bearing securities | 1.82% | 33.33% | Pass |
| Accounts receivable | 4.51% | 49.00% | Pass |
| Non-permissible income | 0.66% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 31.80 | NEUTRAL |
| Stochastic %K (14) | 6.85 | BUY |
| CCI (20) | -210.77 | BUY |
| Williams %R (14) | -93.15 | BUY |
| MACD (12,26,9) | -5.36 | SELL |
| ROC (10) | -8.47 | SELL |
| Momentum (10) | -49.80 | SELL |
| EMA (10) | 565.96 | SELL |
| SMA (10) | 571.38 | SELL |
| EMA (20) | 570.44 | SELL |
| SMA (20) | 575.40 | SELL |
| EMA (30) | 569.39 | SELL |
| SMA (30) | 572.61 | SELL |
| EMA (50) | 562.62 | SELL |
| SMA (50) | 571.18 | SELL |
| EMA (100) | 547.31 | SELL |
| SMA (100) | 533.54 | BUY |
| EMA (200) | 539.54 | SELL |
| SMA (200) | 526.81 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Diagnostics & Research
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
